Jyong Biotech Ltd. Financials
This page shows Jyong Biotech Ltd. (MENS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Jyong Biotech Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Jyong Biotech Ltd.'s current ratio of 0.02 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
For every $1 of reported earnings, Jyong Biotech Ltd. generates $0.59 in operating cash flow (-$2.6M OCF vs -$4.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Jyong Biotech Ltd. earns $-93.2 in operating income for every $1 of interest expense (-$2.8M vs $30K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Jyong Biotech Ltd.'s EBITDA was -$2.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Jyong Biotech Ltd. reported -$4.4M in net income in fiscal year 2025.
Cash & Balance Sheet
Jyong Biotech Ltd. held $2.3M in cash against $0 in long-term debt as of fiscal year 2025.
Jyong Biotech Ltd. had 76M shares outstanding in fiscal year 2025.
Margins & Returns
Capital Allocation
Jyong Biotech Ltd. invested $1.1M in research and development in fiscal year 2025.
Jyong Biotech Ltd. spent $16.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
MENS Income Statement
MENS Balance Sheet
MENS Cash Flow Statement
MENS Financial Ratios
Note: Shareholder equity is negative (-$36.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Jyong Biotech Ltd. profitable?
No, Jyong Biotech Ltd. (MENS) reported a net income of -$4.4M in fiscal year 2025.
What is Jyong Biotech Ltd.'s EBITDA?
Jyong Biotech Ltd. (MENS) had EBITDA of -$2.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Jyong Biotech Ltd.'s operating cash flow?
Jyong Biotech Ltd. (MENS) generated -$2.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Jyong Biotech Ltd.'s total assets?
Jyong Biotech Ltd. (MENS) had $6.4M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Jyong Biotech Ltd. spend on research and development?
Jyong Biotech Ltd. (MENS) invested $1.1M in research and development during fiscal year 2025.
What is Jyong Biotech Ltd.'s current ratio?
Jyong Biotech Ltd. (MENS) had a current ratio of 0.02 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Jyong Biotech Ltd.'s return on assets (ROA)?
Jyong Biotech Ltd. (MENS) had a return on assets of -69.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Jyong Biotech Ltd.'s cash runway?
Based on fiscal year 2025 data, Jyong Biotech Ltd. (MENS) had $2.3M in cash against an annual operating cash burn of $2.6M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Jyong Biotech Ltd.'s earnings high quality?
Jyong Biotech Ltd. (MENS) has an earnings quality ratio of 0.59x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Jyong Biotech Ltd. cover its interest payments?
Jyong Biotech Ltd. (MENS) has an interest coverage ratio of -93.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Jyong Biotech Ltd.?
Jyong Biotech Ltd. (MENS) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.